Vericel (VCEL) Cash from Investing Activities (2010 - 2026)
Vericel (VCEL) posted Cash from Investing Activities of -$2.8 million for Q2 2026, up 32.87% sequentially from -$4.2 million in Q1 2026, and up 68.76% YoY from -$1.7 million in Q2 2025.
Analysis
Vericel (VCEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Vericel has reported Cash from Investing Activities for 17 years, with the latest figure at -$2.8 million in Q2 2026.
- Quarterly Cash from Investing Activities rose 68.76% year-over-year to -$2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$26.8 million (up 55.38% YoY) and the FY2025 annual result came in at -$43.9 million, up 44.41% from the prior year.
- Cash from Investing Activities advanced to -$2.8 million in Q2 2026 per VCEL's latest filing, from -$4.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $4.6 million in Q3 2023 and troughed at -$25.5 million in Q1 2024.
- A 5-year average of -$9.4 million and a median of -$8.6 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 1252.73% in 2022, then surged 663.01% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$21.7 million in 2022, then soared by 62.78% to -$8.1 million in 2023, then sank by 81.14% to -$14.7 million in 2024, then retreated by 11.87% to -$16.4 million in 2025, then soared by 82.79% to -$2.8 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.8 million, -$4.2 million, and -$16.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | -2.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.82 Mn |
| Mar 31, 2026 | -4.20 Mn |
| Dec 31, 2025 | -16.39 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Mar 31, 2025 | -15.14 Mn |
| Dec 31, 2024 | -14.65 Mn |
| Sep 30, 2024 | -21.21 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Sep 30, 2023 | 4.57 Mn |
| Jun 30, 2023 | -2.41 Mn |
| Mar 31, 2023 | 2.80 Mn |
| Dec 31, 2022 | -21.73 Mn |
| Sep 30, 2022 | -811,000.00 |
| Jun 30, 2022 | -3.00 Mn |
| Mar 31, 2022 | -10.67 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | -2.63 Mn |